Literature DB >> 23269278

FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.

Biswajyoti Sahu1, Marko Laakso, Päivi Pihlajamaa, Kristian Ovaska, Ievgenii Sinielnikov, Sampsa Hautaniemi, Olli A Jänne.   

Abstract

The forkhead protein FoxA1 has functions other than a pioneer factor, in that its depletion brings about a significant redistribution in the androgen receptor (AR) and glucocorticoid receptor (GR) cistromes. In this study, we found a novel function for FoxA1 in defining the cell-type specificity of AR- and GR-binding events in a distinct fashion, namely, for AR in LNCaP-1F5 cells and for GR in VCaP cells. We also found different, cell-type and receptor-specific compilations of cis-elements enriched adjacent to the AR- and GR-binding sites. The AR pathway is central in prostate cancer biology, but the role of GR is poorly known. We find that AR and GR cistromes and transcription programs exhibit significant overlap, and GR regulates a large number of genes considered to be AR pathway-specific. This raises questions about the role of GR in maintaining the AR pathway under androgen-deprived conditions in castration-resistant prostate cancer patients. However, in the presence of androgen, ligand-occupied GR acts as a partial antiandrogen and attenuates the AR-dependent transcription program. . ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23269278     DOI: 10.1158/0008-5472.CAN-12-2350

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  113 in total

1.  Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping.

Authors:  Joanna K Lempiäinen; Einari A Niskanen; Kaisa-Mari Vuoti; Riikka E Lampinen; Helka Göös; Markku Varjosalo; Jorma J Palvimo
Journal:  Mol Cell Proteomics       Date:  2017-06-13       Impact factor: 5.911

2.  Tissue-specific pioneer factors associate with androgen receptor cistromes and transcription programs.

Authors:  Päivi Pihlajamaa; Biswajyoti Sahu; Lauri Lyly; Viljami Aittomäki; Sampsa Hautaniemi; Olli A Jänne
Journal:  EMBO J       Date:  2014-01-22       Impact factor: 11.598

Review 3.  Vitamin D receptor and RXR in the post-genomic era.

Authors:  Mark D Long; Lara E Sucheston-Campbell; Moray J Campbell
Journal:  J Cell Physiol       Date:  2015-04       Impact factor: 6.384

Review 4.  Corticosteroids in the management of prostate cancer: a critical review.

Authors:  Chukwuma Ndibe; Christopher G Wang; Guru Sonpavde
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 5.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 6.  The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside.

Authors:  Jieping Hu; Qingke Chen
Journal:  Int Urol Nephrol       Date:  2016-12-16       Impact factor: 2.370

Review 7.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

8.  α-Viniferin activates autophagic apoptosis and cell death by reducing glucocorticoid receptor expression in castration-resistant prostate cancer cells.

Authors:  Kejun Cheng; Xi Liu; Lu Chen; Jian-Min Lv; Fa-Jun Qu; Xiu-Wu Pan; Lin Li; Xin-Gang Cui; Yi Gao; Dan-Feng Xu
Journal:  Med Oncol       Date:  2018-06-15       Impact factor: 3.064

9.  Forkhead box A3 mediates glucocorticoid receptor function in adipose tissue.

Authors:  Xinran Ma; Lingyan Xu; Elisabetta Mueller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-08       Impact factor: 11.205

10.  NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression.

Authors:  Magdalena M Grabowska; Amicia D Elliott; David J DeGraff; Philip D Anderson; Govindaraj Anumanthan; Hironobu Yamashita; Qian Sun; David B Friedman; David L Hachey; Xiuping Yu; Jonathan H Sheehan; Jung-Mo Ahn; Ganesh V Raj; David W Piston; Richard M Gronostajski; Robert J Matusik
Journal:  Mol Endocrinol       Date:  2014-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.